Drug intelligence / Profile preview

recombinant SLIT2 peptide

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Intranasal, Intravenous
01

Overview

Recombinant SLIT2 peptide (or protein) is a recombinant version of the human Slit Guidance Ligand 2 (SLIT2) glycoprotein, a secreted extracellular matrix protein that plays a key role in axon guidance, cell migration, and angiogenesis. SLIT2 acts primarily by binding to Roundabout (ROBO) receptors, particularly ROBO1 and ROBO2. In oncology, SLIT2 has been shown to function as a context-dependent tumor suppressor. In acute myeloid leukemia (AML), SLIT2 expression is often downregulated, and treatment with recombinant SLIT2 peptide has been shown to exert cytostatic effects, inhibiting leukemic cell proliferation and delaying leukemogenesis in vivo. It has also been investigated in preclinical models of breast cancer, lung cancer, glioblastoma, and neonatal brain injuries such as germinal matrix hemorrhage and hypoxic-ischemic encephalopathy.

Other names
recombinant human SLIT2recombinant human SLIT2 proteinrecombinant Slit Guidance Ligand 2recombinant SLIT2recombinant SLIT2 proteinrecombinant Slit2-NrSlit2rSlit-2rSlit 2rSlit2-NrSlit-2-NrSlit 2-N
02

Targets

ROBO1 (Roundabout guidance receptor 1)ROBO2 (Roundabout homolog 2)

Beyond the preview

Go deeper on recombinant SLIT2 peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant SLIT2 peptide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call